List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
At the heart of precision oncology is the need to increase our understanding and knowledge of surface proteins found on tumour cells. Here Roman Thomas, CEO of DISCO Pharmaceuticals, explains how it is using cutting-edge technology to explore the surfaceome – a map of the proteins on the cell’s surface…
Researchers have discovered that pancreatic cancer’s resistance to chemotherapy is related to the physical stiffness of the extracellular matrix.
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
A new assay has been developed which enables the detailing of intact proviral genomes of under-studied HIV strains.
Researchers found that tumour beta cells lose their repression marks and express elevated levels of oncogenes.
The hiPSC-derived skeletal muscle model is the first to uncover the biological mechanisms underlying loss of mobility.
Researchers have designed synthetic, soluble versions of cell membrane proteins, which will enable faster and easier screening for new drugs.
Mini-colons, which closely resemble in vivo tissue, were used for several applications, including the characterisation of anticancer drug toxicity profiles.
20 June 2024 | By Eurofins DiscoverX
Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules.
Researchers have developed a 3D approach to improve the characterisation of pancreatic intraepithelial neoplasias.
The novel drug, ETD001, could provide an improved approach for mucus clearance in cystic fibrosis patients.
Researchers have developed a new in vitro co-culture system which enables an in-depth molecular analysis of atherosclerosis.
Researchers found, using human respiratory epithelium organoids, that P. aeruginosa breaches respiratory epithelia by goblet cell invasion.
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
Researchers have identified a new biological pathway driving IBD and similar conditions that could be targeted with MEK inhibitors.
